iBio, Inc.: iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio
SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in collaboration with AstralBio Inc., announced today the developme ...
iBio, AstralBio announce development of antibody inhibiting Activin E
Bio (IBIO) in collaboration with AstralBio announced the development of an antibody that inhibits the function of Activin E, a promising ...
iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio
Achievement strengthens iBio’s partnered cardiometabolic and obesity program while showcasing its proprietary AI-driven drug ...
BioWorld2d
Ibio licenses long-acting anti-myostatin antibody from Astralbio
Ibio Inc. has expanded its cardiometabolic and obesity treatment development program by in-licensing a long-acting anti-myostatin antibody from Astralbio Inc. The antibody, now named IBIO-600, was ...
iBio Expands Pipeline with New Antibody Agreement
An update from Ibio ( (IBIO) ) is now available. iBio, Inc. announced an exclusive agreement with AstralBio to license a long ...
FierceBiotech6d
iBio pens $29M biobucks deal with AstralBio for obesity med designed to preserve muscle mass
San Diego-based iBio has signed a backloaded agreement with its existing partner AstralBio for a preclinical anti-myostatin ...